BIOTECHNOLOGY overview

iNtRON has confirmed the efficacy of BAL200, a novel endolysin biologic for Inhalational Anthrax PR Newswire BOSTON and SEOUL, Korea, Jan. 25, 2023 Confirmed antibacterial efficacy against a variety of anthrax strains including the one used in the 2001 anthrax attack Provides the most potent bactericidal ability that no other PEP antibiotics in the market can exhibit Further developments are planned to conduct with a licensing/collaboration partner BOSTON and SEOUL, Korea , Jan. 25, 2023...

RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, today announced that Shaun Bagai, Chief Executive Officer, is scheduled to present virtually at the Sequire Biotechnology Conference on Thursday, February 2, 2023 at 4 p.m. (ET). To register for the event, visit the Sequire Biotechnology Conference website . During the webinar, Mr. Bagai will discuss the company’s mission to become a leading provider in oncology therapy by disrupting...

CALGARY, AB / ACCESSWIRE / January 23, 2023 / Asia Green Biotechnology Corp. ("Asia Green" or the "Company") (CSE:ASIA) announces that it has obtained additional financing and completed the next payment to facilitate its continuing scientific trials activities with respect to treatments for migraine and related health issues being developed by Pathway RX Inc. and Swysh Inc., Asia Green's research and development partners. This action comes as a consequence of the partners' completing the Health...

MAIA Biotechnology, Inc. (NYSE American: MAIA ) announced today the advancement of its Telomere-Targeting Molecule Program (“Project T3”). MAIA is designing and evaluating multiple telomere-targeting compounds designed to modify the telomeric structure through the cancer cell - intrinsic telomerase activity - and thus cause the death of these cells. The studies, conducted in vitro in multiple cancer cell lines and in vivo in several pre-clinical cancer models, demonstrated the intended...

-Total gross proceeds from transaction, before payment of transaction expenses, expected to be up to $82 million assuming no redemptions, combining a possible PIPE financing of up to $40 million and up to $42 million held in First Light trust account -Cash resources will fund Calidi’s NeuroNova (CLD-101) and SuperNova (CLD-201) development programs into the 1st half of 2025 through multiple clinical milestones -Calidi’s novel platform addresses a critical obstacle in traditional oncolytic...

MAIA Biotechnology, Inc. (NYSE American: MAIA ) (“MAIA,” “the Company”) announced today that the management team will participate in the four upcoming investor conferences as follows: Biotech Showcase: The Investor Conference for Innovators will be held in-person in San Francisco from January 9-11, and virtually from January 18-19. The MAIA team will host investor meetings and is scheduled to present on Monday, January 9 at 4:00 pm PT. The webcast will be available on the News & Events...

Alpha Healthcare Acquisition Corp. III (Nasdaq: ALPA) (“ALPA”), a special purpose acquisition company led by Mr. Rajiv Shukla, today announced the execution of a definitive business combination agreement with Carmell Therapeutics Corporation (“Carmell ™ ”), a Phase 2-stage biotechnology platform company developing allogeneic plasma-based biomaterials for bone and soft tissue healing indications. Upon closing of the transaction, ALPA will be renamed Carmell Therapeutics Corporation (the...

MAIA Biotechnology, Inc. (NYSE American: MAIA ) (“MAIA,” “the Company”) today announced that it completed a pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) for the planned U.S. expansion of the THIO-101 Phase 2 trial evaluating THIO, an investigational telomere-targeting agent, in patients with advanced non-small cell lung cancer (NSCLC). MAIA received positive feedback from the FDA regarding its manufacturing, preclinical and clinical...